BR112018076247A2 - anticorpos monoclonais quiméricos e humanizados para cd81 - Google Patents

anticorpos monoclonais quiméricos e humanizados para cd81

Info

Publication number
BR112018076247A2
BR112018076247A2 BR112018076247-4A BR112018076247A BR112018076247A2 BR 112018076247 A2 BR112018076247 A2 BR 112018076247A2 BR 112018076247 A BR112018076247 A BR 112018076247A BR 112018076247 A2 BR112018076247 A2 BR 112018076247A2
Authority
BR
Brazil
Prior art keywords
chimeric
monoclonal antibodies
humanized monoclonal
sequences
cdr
Prior art date
Application number
BR112018076247-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Levy Shoshana
Marabelle Aurelien
Rajapaksa Ranjani
Vences-Catalán Felipe
Kuo Chiung-Chi
Liu Jie
Levy Ronald
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of BR112018076247A2 publication Critical patent/BR112018076247A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112018076247-4A 2016-06-16 2017-06-14 anticorpos monoclonais quiméricos e humanizados para cd81 BR112018076247A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351054P 2016-06-16 2016-06-16
US62/351,054 2016-06-16
PCT/US2017/037533 WO2017218691A1 (en) 2016-06-16 2017-06-14 Humanized and chimeric monoclonal antibodies to cd81

Publications (1)

Publication Number Publication Date
BR112018076247A2 true BR112018076247A2 (pt) 2019-03-26

Family

ID=60664252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076247-4A BR112018076247A2 (pt) 2016-06-16 2017-06-14 anticorpos monoclonais quiméricos e humanizados para cd81

Country Status (9)

Country Link
US (1) US10815306B2 (cg-RX-API-DMAC7.html)
EP (1) EP3471762A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019517813A (cg-RX-API-DMAC7.html)
CN (1) CN109414492A (cg-RX-API-DMAC7.html)
BR (1) BR112018076247A2 (cg-RX-API-DMAC7.html)
CA (1) CA3027942A1 (cg-RX-API-DMAC7.html)
MA (1) MA45404A (cg-RX-API-DMAC7.html)
RU (1) RU2019100102A (cg-RX-API-DMAC7.html)
WO (1) WO2017218691A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021150266A1 (en) * 2020-01-21 2021-07-29 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling
WO2024079192A1 (en) 2022-10-12 2024-04-18 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
US8034902B2 (en) * 2005-05-04 2011-10-11 Quark Pharmaceuticals, Inc. Recombinant antibodies against CD55 and CD59 and uses thereof
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US20140030771A1 (en) 2010-06-09 2014-01-30 Richard C. Yu Compositions and methods for increasing oil production and secretion
US8440797B2 (en) * 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
EP2650367A4 (en) * 2010-12-06 2015-07-08 Sumitomo Dainippon Pharma Co Ltd HUMAN MONOCLONAL ANTIBODY
US9725517B2 (en) * 2012-10-26 2017-08-08 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Humanized monoclonal antibodies against the extracellular domain of human death receptor 5

Also Published As

Publication number Publication date
EP3471762A1 (en) 2019-04-24
EP3471762A4 (en) 2020-03-11
CN109414492A (zh) 2019-03-01
WO2017218691A1 (en) 2017-12-21
MA45404A (fr) 2019-04-24
US10815306B2 (en) 2020-10-27
US20190177425A1 (en) 2019-06-13
RU2019100102A (ru) 2020-07-16
CA3027942A1 (en) 2017-12-21
JP2019517813A (ja) 2019-06-27
RU2019100102A3 (cg-RX-API-DMAC7.html) 2020-10-14

Similar Documents

Publication Publication Date Title
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
PH12021550023A1 (en) Humanized anti-tau antibodies
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
TN2016000046A1 (en) Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof
PH12016501212B1 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
ZA201708265B (en) Tigit-binding agents and uses thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
PE20190737A1 (es) Anticuerpos anti-cd27
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
GEP20227438B (en) Pd-1-binding molecules and methods of use thereof
NZ738979A (en) Pd-1 antibodies
NZ595235A (en) Compositions and methods for increasing muscle growth
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
WO2013173496A3 (en) Cd33 antibodies and use of same to treat cancer
EA201890175A1 (ru) Антитела к cd40
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
PH12016501366A1 (en) Novel anti-baff antibodies
EA201992756A3 (ru) Антитела против cd48 и их конъюгаты
NZ611269A (en) Neutralizing anti-ccl20 antibodies

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements